What “The 72-Hour Rule” Update Means for New York State

What “The 72-Hour Rule” Update Means for New York State

Effective February 19, 2026, New York State law permits clinicians to dispense up to 72 hours (equivalent to a 3-day supply) of controlled substances, such as methadone and buprenorphine, for the management of opioid withdrawal while arranging referral and linkage to care for persons with opioid use disorder, as authorized by federal regulations (specifically, the Code of Federal Regulations or CFR number 1306.07). The federal regulations were updated in August 2023, and New York State law is just now catching up. We informally refer to the update as “The 72-Hour Rule.”

Featuring Dr. Linda Wang, this episode reviews what this update means for New York State and how clinicians and healthcare administrators can think about its implementation.

Are you implementing “The 72-Hour Rule” in clinical practice in New York State? We want to hear from you! Please reach out to share your experience: Lauren.walker3@mountsinai.org. Related Content:

  • New York State Senate Bill S3416D: https://www.nysenate.gov/legislation/bills/2025/S3416/amendment/D
  • Code of Federal Regulations (CFR) § 1306.07: https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR1eb5bb3a23fddd0/section-1306.07
  • Skogrand E, et al. (2024). Dispensing methadone at hospital discharge: One hospital’s approach to implementing the “72-hour rule” change. J Addict Med. 2024; 18(1):71-74. doi: 10.1097/ADM.0000000000001246.
  • Shahlapour M, et al. (2024). Novel uses of methadone under the “72-hour rule” to facilitate transitions of care and low-dose buprenorphine induction in an outpatient bridge clinic. J Addict Med. 2024; 18(3):345-347. doi: 10/1097/ADM.0000000000001281.
  • Taylor JL, et al. (2022). Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022; 236:109497. doi: 10.1016/j.drugalcdep.2022.109497.
  • CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health.
  • https://ceitraining.org/

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(63)

Introducing Point-of-Care Testing for Hepatitis C

Introducing Point-of-Care Testing for Hepatitis C

New York State’s Hepatitis C Dashboard shows that in 2023, 4,783 people were newly diagnosed with HCV in the state, an 8% decrease from 2022. Incidence also decreased, with the rate of new HCV infecti...

14 Mai 21min

Cannabis and Pregnancy

Cannabis and Pregnancy

Based on data from 2023-24, roughly 23% of New Yorkers aged 21 or older reported cannabis use in the past 12 months. Although men generally have a higher prevalence of use than women, recent studies s...

20 Apr 22min

CROI 2026 – Live from Denver: What You Need to Know

CROI 2026 – Live from Denver: What You Need to Know

Conference on Retroviruses and Opportunistic Infections (CROI) 2026 took place from February 22 to 25 in Denver, Colorado. CROI is an annual scientific meeting devoted to the understanding, prevention...

7 Apr 15min

Misconceptions about Contraception

Misconceptions about Contraception

Host Dr. Erica Bostick from the University of Rochester Medical Center Division of Adolescent Medicine chats with Dr. Stacy Sun, a double board-certified physician in obstetrics and gynecology and com...

12 Mar 33min

Two New Treatments for Gonorrhea; one is available now!

Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights th...

12 Jan 15min

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV.  Subcutaneous lenacapavir is administer...

20 Nov 202528min

Keeping an Eye on STIs – Have You Heard of TMVII?

Keeping an Eye on STIs – Have You Heard of TMVII?

This month, host Dr. Marguerite Urban chats with Dr. Jason Zucker, an adult and pediatric infectious diseases physician at Columbia University and the assistant medical director of the New York City H...

13 Nov 202518min

Populært innen Fakta

fastlegen
dine-penger-pengeradet
rss-bisarr-historie
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-strid-de-norske-borgerkrigene
foreldreradet
treningspodden
jakt-og-fiskepodden
rss-kunsten-a-leve
mikkels-paskenotter
rss-sunn-okonomi
sinnsyn
hverdagspsyken
rss-kull
rss-sarbar-med-lotte-erik
gravid-uke-for-uke
hagespiren-podcast
rss-bak-luftfarten
fryktlos
rss-impressions-2